About the Company
We do not have any company description for Estrella Immunopharma, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (ESLA) - Yahoo Finance
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital ...
Estrella Immunopharma, Inc. (ESLA) Latest Stock News & Headlines ...
EMERYVILLE, Calif., June 05, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ...
ESLA Estrella Immunopharma, Inc. - Seeking Alpha
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a ...
Estrella Immunopharma, Inc., a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, today announced that ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW ... - Morningstar
About Estrella Immunopharma, Inc. Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancers and autoimmune diseases.
Estrella Immunopharma Achieves Complete Response in First Patient ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-t ...
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose ...
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for ...
Estrella Immunopharma, Inc. (ESLA) Latest Stock News & Headlines ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners EMERYVILLE, Calif., March 05, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating ...
EMERYVILLE, Calif., February 19, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ...
Similar Companies
Loading the latest forecasts...